Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brad Broyles

Psychiatry Leesburg, FL Medical Doctor

NPI 1629033493 CMS profile 921878

2018 Talley Rd, Leesburg, FL 34748

Open in the dashboard

General payments

$3,132

164 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brad Broyles of Leesburg, FL is reported in the CMS Open Payments database as having received $3,132 across 164 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Psychiatry profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $692 29
2024 General $443 20
2023 General $365 21
2022 General $587 36
2021 General $442 24
2020 General $192 13
2019 General $410 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brad Broyles
  • Psychiatry median
  • Middle half of Psychiatry
  • National median

In program year 2025, general payments to Brad Broyles were reported at $692. Among 14,155 Psychiatry profiles paid that year, the median was $180 and the middle half received between $58 and $685.

Show as a table
Year Brad Broyles Psychiatry median Middle half National median
2019 $410 $184 $59–$605 $163
2020 $192 $119 $36–$372 $114
2021 $442 $143 $43–$576 $132
2022 $587 $153 $50–$590 $149
2023 $365 $170 $56–$651 $160
2024 $443 $179 $57–$673 $164
2025 $692 $180 $58–$685 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alkermes, Inc. $742 41 payments
  2. Neurocrine Biosciences, Inc. $708 39 payments
  3. Janssen Pharmaceuticals, Inc $516 31 payments
  4. ITI, Inc. $363 18 payments
  5. E.R. Squibb & Sons, L.L.C. $274 8 payments
  6. Teva Pharmaceuticals USA, Inc. $227 12 payments
  7. AbbVie, Inc. $104 5 payments
  8. Indivior Inc. $80 5 payments
  9. Vanda Pharmaceuticals Inc. $61 2 payments
  10. Otsuka America Pharmaceutical, Inc. $56 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,104 163 payments
  2. Education $27 1 payment
Products named General payments · program years 2019–2025
  1. ARISTADA Cns $686 37 payments
  2. ARISTADA Cns $686 37 payments
  3. ARISTADA INITIO $546 29 payments
  4. ARISTADA Cns $539 28 payments
  5. ARISTADA Cns $539 28 payments
  6. INVEGA SUSTENNA $516 31 payments
  7. INVEGA TRINZA $357 22 payments
  8. CAPLYTA $348 17 payments
  9. LYBALVI $343 21 payments
  10. INGREZZA $342 20 payments
  11. Other $1,563 81 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 97 drugs

Part D claims

5,791

Median for Psychiatry & Neurology: 100

Drug cost

$1,537,931

Median for Psychiatry & Neurology: $2,986

Branded share of claims

18.9%

Median for Psychiatry & Neurology: 16.2%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 140 $482,583
Invega Trinza Paliperidone Palmitate Brand 47 $441,151
Ingrezza Valbenazine Tosylate Brand 16 $128,375
Vraylar Cariprazine Hcl Brand 72 $95,020
Clozapine Odt Clozapine Brand 129 $47,020
Perseris Risperidone Brand 13 $42,747
Aripiprazole Odt Aripiprazole Brand 59 $32,279
Emsam Selegiline Brand 13 $31,646
Caplyta Lumateperone Tosylate Brand 17 $27,072
Quetiapine Fumarate Er Quetiapine Fumarate Brand 39 $16,798

The 10 drugs with the highest cost, of 97 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,755 Part D prescribers listed as Psychiatry & Neurology; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
  • ITI, Inc. $163
$163 17 —
INGREZZA
  • Neurocrine Biosciences, Inc. $77
$77 16 —
COBENFY
  • E.R. Squibb & Sons, L.L.C. $45
$45 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $44
$44 140 —
INVEGA TRINZA
  • Janssen Pharmaceuticals, Inc $44
$44 47 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

164 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Psychiatry in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record